Patents by Inventor Miles Congreve
Miles Congreve has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10030012Abstract: The present invention provides muscarinic M4 receptor agonists of formula (I) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, R, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases such as schizophrenia, Alzheimer's disease and various cognitive disorders as well as in the treatment or alleviation of pain.Type: GrantFiled: March 10, 2017Date of Patent: July 24, 2018Assignee: Heptares Therapeutics LimitedInventors: David Livermore, Kathryn White, Miles Congreve, Giles Brown, Michael O'Brien
-
Publication number: 20170183338Abstract: The present invention provides muscarinic M4 receptor agonists of formula (I) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, R, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases such as schizophrenia, Alzheimer's disease and various cognitive disorders as well as in the treatment or alleviation of pain.Type: ApplicationFiled: March 10, 2017Publication date: June 29, 2017Inventors: David Livermore, Kathryn White, Miles Congreve, Giles Brown, Michael O'Brien
-
Patent number: 9593106Abstract: The present invention provides muscarinic M4 receptor agonists of formula (I) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, R, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases such as schizophrenia, Alzheimer's disease and various cognitive disorders as well as in the treatment or alleviation of pain.Type: GrantFiled: February 7, 2014Date of Patent: March 14, 2017Assignee: Heptares Therapeutics LimitedInventors: David Livermore, Kathryn White, Miles Congreve, Giles Brown, Michael O'Brien
-
Publication number: 20150376179Abstract: The present invention provides muscarinic M4 receptor agonists of formula (I) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, R, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases such as schizophrenia, Alzheimer's disease and various cognitive disorders as well as in the treatment or alleviation of pain.Type: ApplicationFiled: February 7, 2014Publication date: December 31, 2015Inventors: David Livermore, Kathryn White, Miles Congreve, Giles Brown, Michael O'Brien
-
Patent number: 9187451Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R1-R6 are as defined herein.Type: GrantFiled: November 16, 2012Date of Patent: November 17, 2015Assignee: Heptares Therapeutics LimitedInventors: Miles Congreve, Giles Brown, Julie Cansfield, Benjamin Tehan
-
Publication number: 20140329803Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R1-R6 are as defined herein.Type: ApplicationFiled: November 16, 2012Publication date: November 6, 2014Inventors: Miles Congreve, Giles Brown, Julie Cansfield, Benjamin Tehan
-
Publication number: 20110059992Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: November 11, 2010Publication date: March 10, 2011Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LTD.Inventors: James Arnold, Phil Edwards, Mark Sylvester, Stefan Berg, Jörg Holenz, Annika Kers, Karin Kolmodin, Laszlo Rakos, Liselotte Öhberg, Rotticci Didier, Gianni Chessari, Miles Congreve, Christopher Murray, Sahil Patel
-
Patent number: 7855213Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: GrantFiled: June 13, 2007Date of Patent: December 21, 2010Assignees: AstraZeneca AB, Astex Therapeutics Ltd.Inventors: James Arnold, Phil Edwards, Mark Sylvester, Stefan Berg, Jörg Holenz, Annika Kers, Karin Kolmodin, Laszlo Rakos, Liselotte Öhberg, Rotticci Didier, Gianni Chessari, Miles Congreve, Christopher Murray, Sahil Patel
-
Publication number: 20080171771Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: June 13, 2007Publication date: July 17, 2008Applicants: AstraZeneca AB, Astex Therapeutics LtdInventors: James Arnold, Phil Edwards, Mark Sylvester, Stefan Berg, Jorg Holenz, Annika Kers, Karin Kolmodin, Laszlo Rakos, Liselotte Ohberg, Rotticci Didier, Gianni Chessari, Miles Congreve, Christopher Murray, Sahil Patel
-
Publication number: 20070276026Abstract: The invention provides compounds of the formula (I): or salts, tautomers, solvates and N-oxides thereof, wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1-5 hydrocarbyloxy; R4 is selected from hydrogen; a group —(O)n—R7 where n is 0 or 1 and R7 is an optionally substituted acyclic C1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C1-5 hydrocarbyl-amino; or R3 and R4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR5R6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The compounds have activity as Hsp90 inhibitors.Type: ApplicationFiled: March 1, 2007Publication date: November 29, 2007Applicant: ASTEX THERAPEUTICS LIMITEDInventors: Gianni Chessari, Miles Congreve, Martyn Frederickson, Christopher Murray, Eva Navarro, Alison Woolford
-
Publication number: 20070259871Abstract: The invention provides compounds of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1-5 hydrocarbyloxy; R4 is selected from hydrogen; a group —(O)n—R7 where n is 0 or 1 and R7 is an optionally substituted acyclic C1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C1-5 hydrocarbyl-amino; or R3 and R4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR5R6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The compounds have activity as Hsp90 inhibitors.Type: ApplicationFiled: March 1, 2007Publication date: November 8, 2007Applicant: ASTEX THERAPEUTICS LIMITEDInventors: Gianni Chessari, Maria Carr, Miles Congreve, Robert Downham, Martyn Frederickson, Christopher Murray, Eva Navarro, Michael O'Brien, Theresa Phillips, Andrew Woodhead, Alison Woolford
-
Publication number: 20070259886Abstract: Compounds having the formula (I): and in particular, those of subgenus VIIa are disclosed as inhibits or modulators of the activity of the heat shock protein Hsp90. As such they are useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate cancer, lung cancer, gastrointestinal stromal tumor, breast cancer and melanoma.Type: ApplicationFiled: March 1, 2007Publication date: November 8, 2007Applicant: ASTEX THERAPEUTICS, LTD.Inventors: Gianni Chessari, Maria Carr, Miles Congreve, Robert Downham, Martyn Frederickson, Christopher Murray, Eva Navarro, Michael O'Brien, Theresa Phillips, Andrew Woodhead
-
Publication number: 20070129281Abstract: The invention provides novel inhibitors of protein tyrosine phosphatase sulfenyl amide and their use in medicine, for example in the treatment or prevention of disease states such as cancer, diabetes, rheumatoid arthritis and hypertension. Also provided are novel crystal structures and the use of the crystal structures and their X-ray coordinates in the development of new drugs.Type: ApplicationFiled: April 1, 2004Publication date: June 7, 2007Inventors: Robin Carr, Miles Congreve, Dominic Tisi, Robert Leon Van Montfort, Nicola Wallis, Glyn Williams, Harren Jhoti
-
Publication number: 20070088068Abstract: A compound of formula (I) and processes for the preparation thereof.Type: ApplicationFiled: November 8, 2006Publication date: April 19, 2007Inventors: Miles Congreve, Gerard Giblin, Andrew Mason, Neil Miller, Susan Roomans, Ann Walker
-
Publication number: 20060159226Abstract: A method for identifying a ligand of a target macromolecule is disclosed, comprising the steps of: soaking one or more crystals of the target macromolecule in a solution containing a collection of compounds generated in situ or separate from the crystal, where the solution has been prepared without the purification of the synthesized collection of compounds; obtaining an X-ray crystal diffraction pattern of the soaked macromolecule crystal; and using said X-ray crystal diffraction pattern to identify any compound bound to the macromolecule crystal, said compound being a ligand of the target macromolecule.Type: ApplicationFiled: December 22, 2003Publication date: July 20, 2006Inventors: Harren Jhoti, Miles Congreve, Marc O'Reilly, Paul Wyatt
-
Publication number: 20060063782Abstract: Compounds of the formula (I), wherein: —X?Y— is selected from —CR<2>=CR<3>— and —CR<2>?N—; R<1> is selected from H, halo, NRR?, NHC(?O)R, NHC(?O)NRR?, NH2SO2R, and C(?O)NRR?; R<2> and R<3> (where present) are independently selected from H, optionally substituted C1-7 alkyl, optionally substituted C5-20 aryl, optionally substituted C3-20 heterocyclyl, halo, amino, amido, hydroxy, ether, thio, thioether, acylamido, ureido and sulfonamino; R<4> is an optionally substituted C5-20 aryl or C5-20 heteroaryl group; and R<5> is selected from R<5?>, halo, NHR<5?>, C(?O)NHR<5?>, OR<5?>, SR<5?>, NHC(?O)R<5?>, NHC(?O)NHR<5?>, NHS(?O)R<5?>, wherein R<5?> is H or C1-3 alkyl (optionally substituted by halo, NH2, OH, SH) are disclosed for use in therapy and for treating diseases ameliorated by inhibiting p38 MAP kinase.Type: ApplicationFiled: July 3, 2003Publication date: March 23, 2006Inventors: Christopher Murray, Michael Hartshorn, Martyn Frederickson, Miles Congreve, Alessandro Padova, Steven Woodhead, Adrian Gill, Andrew Woodhead
-
Publication number: 20050124620Abstract: Compounds are disclosed of the formula (I): in which U, T, V and W are each a nitrogen atom or carbon atom. When U, T, V or W is a carbon atom, it may be substituted. The compounds are inhibitors of p38 MAP kinase and are useful for treating inflammatory diseases such as arthritis.Type: ApplicationFiled: October 8, 2004Publication date: June 9, 2005Inventors: Martyn Frederickson, Adrian Gill, Alessandro Padova, Miles Congreve
-
Publication number: 20050080257Abstract: The present invention relates to a compound of formula (I): corresponding pharmaceutical compositions, preparation processes, and/or methods of using the aforementioned compounds and/or compositions.Type: ApplicationFiled: February 7, 2002Publication date: April 14, 2005Inventors: Miles Congreve, Gerard Giblin, Neil Miller, Susan Roomans, Ann Walker, Andrew Mason
-
Publication number: 20040039020Abstract: The present invention relates to a pharmaceutical formulation suitable for nebulisation which comprises an aqueous suspension of (2S)-3-[4-({[4-(aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-{[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino] propanoic acid or a salt or solvate thereof. Methods and uses of the formulation in the treatment of respiratory disorders such as asthma are also described.Type: ApplicationFiled: August 15, 2003Publication date: February 26, 2004Inventors: Duncan Armour, David Brown, Miles Congreve, Paul Gore, Darren Green, Stuart Holman, Torquil Jack, Steven Keeling, Andrew Mason, Karen Morriss, Nigel Ramsden, Marian Thomas, Peter Ward
-
Publication number: 20040039021Abstract: The present invention relates to a pharmaceutical aerosol formulation comprising a hydrofluoroalkane (HFA) propellant having suspended therein particulate (2S)-3-[4-({[4-(aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-[((2S)-4-methyl-2-{[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino] propanoic acid or a salt or solvate thereof. Methods and uses of the formulation in the treatment of respiratory disorders are also described, as are canisters and metered dose inhalers containing said formulation.Type: ApplicationFiled: August 21, 2003Publication date: February 26, 2004Inventors: Duncan Robert Armour, David Brown, Miles Congreve, Paul Gore, Darren Victor, Steven Green, Stuart Holman, Torquil Iain, Maclean Jack, Steven Philip Keeling, Andrew McMurtrie Mason, Karen Morriss, Nigel Grahame Ramsden, Marian Thomas, Peter Ward